Home » FDA Approves Sepracor's Xopenex HFA Metered-Dose Inhaler
FDA Approves Sepracor's Xopenex HFA Metered-Dose Inhaler
The FDA has approved Sepracor's new drug application for Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane metered-dose inhaler for the treatment or prevention of bronchospasm in adults, adolescents and children 4 years of age and older with reversible obstructive airway disease.
Reversible obstructive airway disease includes respiratory disorders such as asthma and chronic obstructive pulmonary disease.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May